Basal/HER2 breast carcinomas

References

• Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of convenience?. Nat Rev Clin Oncol 2010; 7:683 - 92; http://dx.doi.org/10.1038/nrclinonc.2010.154; PMID: 20877296
   PubMed Web of Science ®Google Scholar
• Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747 - 52; http://dx.doi.org/10.1038/35021093; PMID: 10963602
   PubMed Web of Science ®Google Scholar
• Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98:10869 - 74; http://dx.doi.org/10.1073/pnas.191367098; PMID: 11553815
   PubMed Web of Science ®Google Scholar
• Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100:8418 - 23; http://dx.doi.org/10.1073/pnas.0932692100; PMID: 12829800
   PubMed Web of Science ®Google Scholar
• Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 2010; 28:92 - 8; http://dx.doi.org/10.1200/JCO.2008.19.9844; PMID: 19933921
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al, Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:1659 - 72; http://dx.doi.org/10.1056/NEJMoa052306; PMID: 16236737
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr., Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673 - 84; http://dx.doi.org/10.1056/NEJMoa052122; PMID: 16236738
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N Engl J Med 2005; 353:1734 - 6; http://dx.doi.org/10.1056/NEJMe058196; PMID: 16236745
   PubMed Web of Science ®Google Scholar
• Gonzalez-Angulo AM, Hortobágyi GN, Esteva FJ. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer. Oncologist 2006; 11:857 - 67; http://dx.doi.org/10.1634/theoncologist.11-8-857; PMID: 16951389
   PubMed Web of Science ®Google Scholar
• Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 2009; 27:5700 - 6; http://dx.doi.org/10.1200/JCO.2009.23.2025; PMID: 19884543
   PubMed Web of Science ®Google Scholar
• Chavez-MacGregor M, Gonzalez-Angulo AM. HER2-neu positivity in patients with small and node-negative breast cancer (pT1a,b,N0,M0): a high risk group?. Clin Adv Hematol Oncol 2009; 7:591 - 8; PMID: 20020671
   PubMedGoogle Scholar
• Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20:719 - 26; http://dx.doi.org/10.1200/JCO.20.3.719; PMID: 11821453
   PubMed Web of Science ®Google Scholar
• Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006; 3:269 - 80; http://dx.doi.org/10.1038/ncponc0509; PMID: 16683005
   PubMedGoogle Scholar
• Nahta R, Esteva FJ. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res 2006; 8:215; http://dx.doi.org/10.1186/bcr1612; PMID: 17096862
   PubMed Web of Science ®Google Scholar
• Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007; 18:977 - 84; http://dx.doi.org/10.1093/annonc/mdl475; PMID: 17229773
   PubMed Web of Science ®Google Scholar
• Nahta R, Esteva FJ. Trastuzumab: triumphs and tribulations. Oncogene 2007; 26:3637 - 43; http://dx.doi.org/10.1038/sj.onc.1210379; PMID: 17530017
   PubMed Web of Science ®Google Scholar
• Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009; 27:5838 - 47; http://dx.doi.org/10.1200/JCO.2009.22.1507; PMID: 19884552
   PubMed Web of Science ®Google Scholar
• Esteva FJ, Yu D, Hung MC, Hortobagyi GN. Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat Rev Clin Oncol 2010; 7:98 - 107; http://dx.doi.org/10.1038/nrclinonc.2009.216; PMID: 20027191
   PubMed Web of Science ®Google Scholar
• Pusztai L. Molecular heterogeneity of breast cancer: implications for treatment and clinical trial design. Breast Cancer Res 2009; 11:Suppl 1 S4; http://dx.doi.org/10.1186/bcr2265; PMID: 20030879
   PubMedGoogle Scholar
• Roukos DH. Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer. J Clin Oncol 2010; 28:e279 - 80, author reply e282-3; http://dx.doi.org/10.1200/JCO.2009.27.7061; PMID: 20406920
   PubMedGoogle Scholar
• Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295:2492 - 502; http://dx.doi.org/10.1001/jama.295.21.2492; PMID: 16757721
   PubMed Web of Science ®Google Scholar
• Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008; 109:123 - 39; http://dx.doi.org/10.1007/s10549-007-9632-6; PMID: 17578664
   PubMed Web of Science ®Google Scholar
• Perou CM, Børresen-Dale AL. Systems biology and genomics of breast cancer. Cold Spring Harb Perspect Biol 2011; 3; http://dx.doi.org/10.1101/cshperspect.a003293; PMID: 21047916
   PubMed Web of Science ®Google Scholar
• Rakha EA, Ellis IO. Triple-negative/basal-like breast cancer: review. [review] Pathology 2009; 41:40 - 7; http://dx.doi.org/10.1080/00313020802563510; PMID: 19089739
   PubMed Web of Science ®Google Scholar
• Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 2009; 15:2302 - 10; http://dx.doi.org/10.1158/1078-0432.CCR-08-2132; PMID: 19318481
   PubMed Web of Science ®Google Scholar
• Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol 2011; 24:157 - 67; http://dx.doi.org/10.1038/modpathol.2010.200; PMID: 21076464
   PubMed Web of Science ®Google Scholar
• Oliveras-Ferraros C, Vazquez-Martin A, Martin-Castillo B, Cufí S, Del Barco S, Lopez-Bonet E, et al. Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin). Biochem Biophys Res Commun 2010; 397:27 - 33; http://dx.doi.org/10.1016/j.bbrc.2010.05.041; PMID: 20470755
   PubMed Web of Science ®Google Scholar
• Oliveras-Ferraros C, Vazquez-Martin A, Martin-Castilló B, Pérez-Martínez MC, Cufí S, Del Barco S, et al. Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin). Int J Oncol 2010; 37:669 - 78; PMID: 20664936
   PubMed Web of Science ®Google Scholar
• Gonzalez-Angulo AM, Hennessy BT, Mills GB. Future of personalized medicine in oncology: a systems biology approach. J Clin Oncol 2010; 28:2777 - 83; http://dx.doi.org/10.1200/JCO.2009.27.0777; PMID: 20406928
   PubMed Web of Science ®Google Scholar
• Ellsworth RE, Decewicz DJ, Shriver CD, Ellsworth DL. Breast cancer in the personal genomics era. Curr Genomics 2010; 11:146 - 61; http://dx.doi.org/10.2174/138920210791110951; PMID: 21037853
   PubMed Web of Science ®Google Scholar
• Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009; 14:320 - 68; http://dx.doi.org/10.1634/theoncologist.2008-0230; PMID: 19346299
   PubMed Web of Science ®Google Scholar
• Roukos DH. Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. Pharmacogenomics J 2011; 11:81 - 92; http://dx.doi.org/10.1038/tpj.2010.81; PMID: 20975737
   PubMed Web of Science ®Google Scholar
• van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347:1999 - 2009; http://dx.doi.org/10.1056/NEJMoa021967; PMID: 12490681
   PubMed Web of Science ®Google Scholar
• Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351:2817 - 26; http://dx.doi.org/10.1056/NEJMoa041588; PMID: 15591335
   PubMed Web of Science ®Google Scholar
• Eichhorn PJ, Baselga J. HER2 signatures in breast cancer: ready to go to print?. J Clin Oncol 2010; 28:1809 - 10; http://dx.doi.org/10.1200/JCO.2009.26.7146; PMID: 20231675
   PubMed Web of Science ®Google Scholar
• Staaf J, Ringnér M, Vallon-Christersson J, Jönsson G, Bendahl PO, Holm K, et al. Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome. J Clin Oncol 2010; 28:1813 - 20; http://dx.doi.org/10.1200/JCO.2009.22.8775; PMID: 20231686
   PubMed Web of Science ®Google Scholar
• Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008; 10:R65; http://dx.doi.org/10.1186/bcr2124; PMID: 18662380
   PubMed Web of Science ®Google Scholar
• Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 2008; 14:5158 - 65; http://dx.doi.org/10.1158/1078-0432.CCR-07-4756; PMID: 18698033
   PubMed Web of Science ®Google Scholar
• Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009; 360:790 - 800; http://dx.doi.org/10.1056/NEJMra0801289; PMID: 19228622
   PubMed Web of Science ®Google Scholar
• Staaf J, Jönsson G, Ringnér M, Vallon-Christersson J, Grabau D, Arason A, et al. High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer. Breast Cancer Res 2010; 12:R25; http://dx.doi.org/10.1186/bcr2568; PMID: 20459607
   PubMed Web of Science ®Google Scholar
• Theillet C. What do we learn from HER2-positive breast cancer genomic profiles?. Breast Cancer Res 2010; 12:107; http://dx.doi.org/10.1186/bcr2571; PMID: 20519027
   PubMed Web of Science ®Google Scholar
• Menendez JA, Mehmi I, Lupu R. Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression. J Clin Oncol 2006; 24:3735 - 46; http://dx.doi.org/10.1200/JCO.2005.04.3489; PMID: 16847284
   PubMed Web of Science ®Google Scholar
• Arteaga CL. Can trastuzumab be effective against tumors with low HER2/Neu (ErbB2) receptors?. J Clin Oncol 2006; 24:3722 - 5; http://dx.doi.org/10.1200/JCO.2006.06.5268; PMID: 16847283
   PubMed Web of Science ®Google Scholar
• de Alava E, Ocaña A, Abad M, Montero JC, Esparís-Ogando A, Rodríguez CA, et al. Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer. J Clin Oncol 2007; 25:2656 - 63; http://dx.doi.org/10.1200/JCO.2006.08.6850; PMID: 17602072
   PubMed Web of Science ®Google Scholar
• Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 2008; 358:1409 - 11; http://dx.doi.org/10.1056/NEJMc0801440; PMID: 18367751
   PubMed Web of Science ®Google Scholar
• Esteva FJ, Yu D, Hung MC, Hortobagyi GN. Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat Rev Clin Oncol 2010; 7:98 - 107; http://dx.doi.org/10.1038/nrclinonc.2009.216; PMID: 20027191
   PubMed Web of Science ®Google Scholar
• Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007; 12:395 - 402; http://dx.doi.org/10.1016/j.ccr.2007.08.030; PMID: 17936563
   PubMed Web of Science ®Google Scholar
• Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D, et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 2007; 13:1198 - 207; http://dx.doi.org/10.1158/1078-0432.CCR-06-1304; PMID: 17317830
   PubMed Web of Science ®Google Scholar
• Bedard PL, Cardoso F, Piccart-Gebhart MJ. Stemming resistance to HER-2 targeted therapy. J Mammary Gland Biol Neoplasia 2009; 14:55 - 66; http://dx.doi.org/10.1007/s10911-009-9116-x; PMID: 19259796
   PubMed Web of Science ®Google Scholar
• Jones RJ, Matsui WH, Smith BD. Cancer stem cells: are we missing the target?. J Natl Cancer Inst 2004; 96:583 - 5; http://dx.doi.org/10.1093/jnci/djh095; PMID: 15100335
   PubMed Web of Science ®Google Scholar
• Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100:3983 - 8; http://dx.doi.org/10.1073/pnas.0530291100; PMID: 12629218
   PubMed Web of Science ®Google Scholar
• Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008; 10:R25; http://dx.doi.org/10.1186/bcr1982; PMID: 18366788
   PubMed Web of Science ®Google Scholar
• Kakarala M, Wicha MS. Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol 2008; 26:2813 - 20; http://dx.doi.org/10.1200/JCO.2008.16.3931; PMID: 18539959
   PubMed Web of Science ®Google Scholar
• Korkaya H, Paulson A, Iovino F, Wicha MS. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 2008; 27:6120 - 30; http://dx.doi.org/10.1038/onc.2008.207; PMID: 18591932
   PubMed Web of Science ®Google Scholar
• Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1:555 - 67; http://dx.doi.org/10.1016/j.stem.2007.08.014; PMID: 18371393
   PubMed Web of Science ®Google Scholar
• Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008; 100:672 - 9; http://dx.doi.org/10.1093/jnci/djn123; PMID: 18445819
   PubMed Web of Science ®Google Scholar
• Magnifico A, Albano L, Campaner S, Delia D, Castiglioni F, Gasparini P, et al. Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab. Clin Cancer Res 2009; 15:2010 - 21; http://dx.doi.org/10.1158/1078-0432.CCR-08-1327; PMID: 19276287
   PubMed Web of Science ®Google Scholar
• Liu S, Wicha MS. Targeting breast cancer stem cells. J Clin Oncol 2010; 28:4006 - 12; http://dx.doi.org/10.1200/JCO.2009.27.5388; PMID: 20498387
   PubMed Web of Science ®Google Scholar
• Debeb BG, Xu W, Woodward WA. Radiation resistance of breast cancer stem cells: understanding the clinical framework. J Mammary Gland Biol Neoplasia 2009; 14:11 - 7; http://dx.doi.org/10.1007/s10911-009-9114-z; PMID: 19252973
   PubMed Web of Science ®Google Scholar
• Eyler CE, Rich JN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 2008; 26:2839 - 45; http://dx.doi.org/10.1200/JCO.2007.15.1829; PMID: 18539962
   PubMed Web of Science ®Google Scholar
• Nguyen NP, Almeida FS, Chi A, Nguyen LM, Cohen D, Karlsson U, et al. Molecular biology of breast cancer stem cells: potential clinical applications. Cancer Treat Rev 2010; 36:485 - 91; http://dx.doi.org/10.1016/j.ctrv.2010.02.016; PMID: 20231058
   PubMed Web of Science ®Google Scholar
• Liu R, Wang X, Chen GY, Dalerba P, Gurney A, Hoey T, et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 2007; 356:217 - 26; http://dx.doi.org/10.1056/NEJMoa063994; PMID: 17229949
   PubMed Web of Science ®Google Scholar
• Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 2009; 106:13820 - 5; http://dx.doi.org/10.1073/pnas.0905718106; PMID: 19666588
   PubMed Web of Science ®Google Scholar
• Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002; 62:4132 - 41; PMID: 12124352
   PubMed Web of Science ®Google Scholar
• Oliveras-Ferraros C, Vazquez-Martin A, Cufí S, Torres-Garcia VZ, Sauri-Nadal T, Barco SD, et al. Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies. Biochem Biophys Res Commun 2011; 407:412 - 9; http://dx.doi.org/10.1016/j.bbrc.2011.03.039; PMID: 21402055
   PubMed Web of Science ®Google Scholar
• Amsterdam A, Sadler KC, Lai K, Farrington S, Bronson RT, Lees JA, et al. Many ribosomal protein genes are cancer genes in zebrafish. PLoS Biol 2004; 2:E139; http://dx.doi.org/10.1371/journal.pbio.0020139; PMID: 15138505
   PubMed Web of Science ®Google Scholar
• Deisenroth C, Zhang Y. Ribosome biogenesis surveillance: probing the ribosomal protein-Mdm2-p53 pathway. Oncogene 2010; 29:4253 - 60; http://dx.doi.org/10.1038/onc.2010.189; PMID: 20498634
   PubMed Web of Science ®Google Scholar
• Dumont N, Wilson MB, Crawford YG, Reynolds PA, Sigaroudinia M, Tlsty TD. Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers. Proc Natl Acad Sci USA 2008; 105:14867 - 72; http://dx.doi.org/10.1073/pnas.0807146105; PMID: 18806226
   PubMed Web of Science ®Google Scholar
• Arima Y, Hayashi N, Hayashi H, Sasaki M, Kai K, Sugihara E, et al. Loss of p16 expression is associated with the stem cell characteristics of surface markers and therapeutic resistance in estrogen receptor-negative breast cancer. Int J Cancer 2012; 130:2568 - 79; http://dx.doi.org/10.1002/ijc.26271; PMID: 21717460
   PubMed Web of Science ®Google Scholar
• Park SY, Lee HE, Li H, Shipitsin M, Gelman R, Polyak K. Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res 2010; 16:876 - 87; http://dx.doi.org/10.1158/1078-0432.CCR-09-1532; PMID: 20103682
   PubMed Web of Science ®Google Scholar
• Ali HR, Dawson SJ, Blows FM, Provenzano E, Pharoah PD, Caldas C. Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance. Breast Cancer Res 2011; 13:R118; http://dx.doi.org/10.1186/bcr3061; PMID: 22112299
   PubMed Web of Science ®Google Scholar
• Lathia JD, Gallagher J, Heddleston JM, Wang J, Eyler CE, Macswords J, et al. Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell 2010; 6:421 - 32; http://dx.doi.org/10.1016/j.stem.2010.02.018; PMID: 20452317
   PubMed Web of Science ®Google Scholar
• Cariati M, Naderi A, Brown JP, Smalley MJ, Pinder SE, Caldas C, et al. Alpha-6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line. Int J Cancer 2008; 122:298 - 304; http://dx.doi.org/10.1002/ijc.23103; PMID: 17935134
   PubMed Web of Science ®Google Scholar
• Jo M, Eastman BM, Webb DL, Stoletov K, Klemke R, Gonias SL. Cell signaling by urokinase-type plasminogen activator receptor induces stem cell-like properties in breast cancer cells. Cancer Res 2010; 70:8948 - 58; http://dx.doi.org/10.1158/0008-5472.CAN-10-1936; PMID: 20940399
   PubMed Web of Science ®Google Scholar
• Shafee N, Smith CR, Wei S, Kim Y, Mills GB, Hortobagyi GN, et al. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res 2008; 68:3243 - 50; http://dx.doi.org/10.1158/0008-5472.CAN-07-5480; PMID: 18451150
   PubMed Web of Science ®Google Scholar
• Vassilopoulos A, Wang RH, Petrovas C, Ambrozak D, Koup R, Deng CX. Identification and characterization of cancer initiating cells from BRCA1 related mammary tumors using markers for normal mammary stem cells. Int J Biol Sci 2008; 4:133 - 42; http://dx.doi.org/10.7150/ijbs.4.133; PMID: 18461147
   PubMed Web of Science ®Google Scholar
• Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer 2005; 5:744 - 9; http://dx.doi.org/10.1038/nrc1694; PMID: 16148886
   PubMed Web of Science ®Google Scholar
• Reka AK, Kurapati H, Narala VR, Bommer G, Chen J, Standiford TJ, et al. Peroxisome proliferator-activated receptor-gamma activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transition. Mol Cancer Ther 2010; 9:3221 - 32; http://dx.doi.org/10.1158/1535-7163.MCT-10-0570; PMID: 21159608
   PubMed Web of Science ®Google Scholar
• Papi A, Guarnieri T, Storci G, Santini D, Ceccarelli C, Taffurelli M, et al. Nuclear receptors agonists exert opposing effects on the inflammation dependent survival of breast cancer stem cells. Cell Death Differ 2012; 19:1208 - 19; http://dx.doi.org/10.1038/cdd.2011.207; PMID: 22261616
   PubMed Web of Science ®Google Scholar
• An Y, Ongkeko WM. ABCG2: the key to chemoresistance in cancer stem cells?. Expert Opin Drug Metab Toxicol 2009; 5:1529 - 42; http://dx.doi.org/10.1517/17425250903228834; PMID: 19708828
   PubMed Web of Science ®Google Scholar
• Ding XW, Wu JH, Jiang CP. ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci 2010; 86:631 - 7; http://dx.doi.org/10.1016/j.lfs.2010.02.012; PMID: 20159023
   PubMed Web of Science ®Google Scholar
• Natarajan K, Xie Y, Baer MR, Ross DD. Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem Pharmacol 2012; 83:1084 - 103; http://dx.doi.org/10.1016/j.bcp.2012.01.002; PMID: 22248732
   PubMed Web of Science ®Google Scholar
• Bendall SC, Stewart MH, Menendez P, George D, Vijayaragavan K, Werbowetski-Ogilvie T, et al. IGF and FGF cooperatively establish the regulatory stem cell niche of pluripotent human cells in vitro. Nature 2007; 448:1015 - 21; http://dx.doi.org/10.1038/nature06027; PMID: 17625568
   PubMed Web of Science ®Google Scholar
• Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, Varticovski L. Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 2008; 10:R10; http://dx.doi.org/10.1186/bcr1855; PMID: 18241344
   PubMed Web of Science ®Google Scholar
• Bachelard-Cascales E, Chapellier M, Delay E, Pochon G, Voeltzel T, Puisieux A, et al. The CD10 enzyme is a key player to identify and regulate human mammary stem cells. Stem Cells 2010; 28:1081 - 8; http://dx.doi.org/10.1002/stem.435; PMID: 20506111
   PubMed Web of Science ®Google Scholar
• Maguer-Satta V, Besançon R, Bachelard-Cascales E. Concise review: neutral endopeptidase (CD10): a multifaceted environment actor in stem cells, physiological mechanisms, and cancer. Stem Cells 2011; 29:389 - 96; http://dx.doi.org/10.1002/stem.592; PMID: 21425402
   PubMed Web of Science ®Google Scholar
• Maguer-Satta V, Chapellier M, Delay E, Bachelard-Cascales E. CD10: a tool to crack the role of stem cells in breast cancer. Proc Natl Acad Sci USA 2011; 108:E1264 - , author reply E1265; http://dx.doi.org/10.1073/pnas.1116567108; PMID: 22109559
   PubMedGoogle Scholar
• Keller PJ, Arendt LM, Skibinski A, Logvinenko T, Klebba I, Dong S, et al. Defining the cellular precursors to human breast cancer. Proc Natl Acad Sci USA 2012; 109:2772 - 7; http://dx.doi.org/10.1073/pnas.1017626108; PMID: 21940501
   PubMed Web of Science ®Google Scholar
• Cufi S, Corominas-Faja B, Vazquez-Martin A, Oliveras-Ferraros C, Dorca J, Bosch-Barrera J, et al. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts. Oncotarget 2012; 3:395 - 8; PMID: 22565037
   PubMed Web of Science ®Google Scholar
• Sarrio D, Franklin CK, Mackay A, Reis-Filho JS, Isacke CM. Epithelial and mesenchymal subpopulations within normal basal breast cell lines exhibit distinct stem cell/progenitor properties. Stem Cells 2012; 30:292 - 303; http://dx.doi.org/10.1002/stem.791; PMID: 22102611
   PubMed Web of Science ®Google Scholar
• Celià-Terrassa T, Meca-Cortés O, Mateo F, de Paz AM, Rubio N, Arnal-Estapé A, et al. Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. J Clin Invest 2012; 122:1849 - 68; http://dx.doi.org/10.1172/JCI59218; PMID: 22505459
   PubMed Web of Science ®Google Scholar
• Blick T, Widodo E, Hugo H, Waltham M, Lenburg ME, Neve RM, et al. Epithelial mesenchymal transition traits in human breast cancer cell lines. Clin Exp Metastasis 2008; 25:629 - 42; http://dx.doi.org/10.1007/s10585-008-9170-6; PMID: 18461285
   PubMed Web of Science ®Google Scholar
• Blick T, Hugo H, Widodo E, Waltham M, Pinto C, Mani SA, et al. Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24 (lo/-) stem cell phenotype in human breast cancer. J Mammary Gland Biol Neoplasia 2010; 15:235 - 52; http://dx.doi.org/10.1007/s10911-010-9175-z; PMID: 20521089
   PubMed Web of Science ®Google Scholar
• Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006; 10:515 - 27; http://dx.doi.org/10.1016/j.ccr.2006.10.008; PMID: 17157791
   PubMed Web of Science ®Google Scholar
• Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, Adélaïde J, Cervera N, et al. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 2006; 25:2273 - 84; http://dx.doi.org/10.1038/sj.onc.1209254; PMID: 16288205
   PubMed Web of Science ®Google Scholar
• Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010; 12:R68; http://dx.doi.org/10.1186/bcr2635; PMID: 20813035
   PubMed Web of Science ®Google Scholar
• Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011; 5:5 - 23; http://dx.doi.org/10.1016/j.molonc.2010.11.003; PMID: 21147047
   PubMed Web of Science ®Google Scholar
• Tanner M, Kapanen AI, Junttila T, Raheem O, Grenman S, Elo J, et al. Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther 2004; 3:1585 - 92; PMID: 15634652
   PubMed Web of Science ®Google Scholar
• Nagy P, Friedländer E, Tanner M, Kapanen AI, Carraway KL, Isola J, et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 2005; 65:473 - 82; PMID: 15695389
   PubMed Web of Science ®Google Scholar
• Jönsson G, Staaf J, Olsson E, Heidenblad M, Vallon-Christersson J, Osoegawa K, et al. High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization. Genes Chromosomes Cancer 2007; 46:543 - 58; http://dx.doi.org/10.1002/gcc.20438; PMID: 17334996
   PubMed Web of Science ®Google Scholar
• Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007; 11:259 - 73; http://dx.doi.org/10.1016/j.ccr.2007.01.013; PMID: 17349583
   PubMed Web of Science ®Google Scholar
• Dhillon J, Astanehe A, Lee C, Fotovati A, Hu K, Dunn SE. The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44+ cells. Oncogene 2010; 29:6294 - 300; http://dx.doi.org/10.1038/onc.2010.365; PMID: 20802512
   PubMed Web of Science ®Google Scholar
• Vazquez-Martin A, Oliveras-Ferraros C, Del Barco S, Martin-Castillo B, Menendez JA. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Res Treat 2011; 126:355 - 64; http://dx.doi.org/10.1007/s10549-010-0924-x; PMID: 20458531
   PubMed Web of Science ®Google Scholar
• Oliveras-Ferraros C, Vazquez-Martin A, Cufí S, Queralt B, Báez L, Guardeño R, et al. Stem cell property epithelial-to-mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux™) efficacy in KRAS wild-type tumor cells. J Cell Biochem 2011; 112:10 - 29; http://dx.doi.org/10.1002/jcb.22952; PMID: 21104905
   PubMed Web of Science ®Google Scholar
• Freytag J, Wilkins-Port CE, Higgins CE, Higgins SP, Samarakoon R, Higgins PJ. PAI-1 mediates the TGF-beta1+EGF-induced “scatter” response in transformed human keratinocytes. J Invest Dermatol 2010; 130:2179 - 90; http://dx.doi.org/10.1038/jid.2010.106; PMID: 20428185
   PubMed Web of Science ®Google Scholar
• White LR, Blanchette JB, Ren L, Awn A, Trpkov K, Muruve DA. The characterization of alpha5-integrin expression on tubular epithelium during renal injury. Am J Physiol Renal Physiol 2007; 292:F567 - 76; http://dx.doi.org/10.1152/ajprenal.00212.2006; PMID: 17018844
   PubMedGoogle Scholar
• Mayanagi T, Sobue K. Diversification of caldesmon-linked actin cytoskeleton in cell motility. Cell Adh Migr 2011; 5:150 - 9; http://dx.doi.org/10.4161/cam.5.2.14398; PMID: 21350330
   PubMed Web of Science ®Google Scholar
• Jung YS, Liu XW, Chirco R, Warner RB, Fridman R, Kim HR. TIMP-1 induces an EMT-like phenotypic conversion in MDCK cells independent of its MMP-inhibitory domain. PLoS One 2012; 7:e38773; http://dx.doi.org/10.1371/journal.pone.0038773; PMID: 22701711
   PubMedGoogle Scholar
• Sarrió D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 2008; 68:989 - 97; http://dx.doi.org/10.1158/0008-5472.CAN-07-2017; PMID: 18281472
   PubMed Web of Science ®Google Scholar
• Girotti MR, Fernández M, López JA, Camafeita E, Fernández EA, Albar JP, et al. SPARC promotes cathepsin B-mediated melanoma invasiveness through a collagen I/α2β1 integrin axis. J Invest Dermatol 2011; 131:2438 - 47; http://dx.doi.org/10.1038/jid.2011.239; PMID: 21850018
   PubMed Web of Science ®Google Scholar
• Fenouille N, Tichet M, Dufies M, Pottier A, Mogha A, Soo JK, et al. The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion. PLoS One 2012; 7:e40378; http://dx.doi.org/10.1371/journal.pone.0040378; PMID: 22911700
   PubMed Web of Science ®Google Scholar
• Meyer MJ, Fleming JM, Ali MA, Pesesky MW, Ginsburg E, Vonderhaar BK. Dynamic regulation of CD24 and the invasive, CD44posCD24neg phenotype in breast cancer cell lines. Breast Cancer Res 2009; 11:R82; http://dx.doi.org/10.1186/bcr2449; PMID: 19906290
   PubMed Web of Science ®Google Scholar
• Korkaya H, Kim GI, Davis A, Malik F, Henry NL, Ithimakin S, et al. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell 2012; 47:570 - 84; http://dx.doi.org/10.1016/j.molcel.2012.06.014; PMID: 22819326
   PubMed Web of Science ®Google Scholar
• Oliveras-Ferraros C, Corominas-Faja B, Cufí S, Vazquez-Martin A, Martin-Castillo B, Iglesias JM, et al. Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin). Cell Cycle 2012; 11:4020 - 32; http://dx.doi.org/10.4161/cc.22225; PMID: 22992620
   PubMed Web of Science ®Google Scholar
• Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010; 29:4741 - 51; http://dx.doi.org/10.1038/onc.2010.215; PMID: 20531305
   PubMed Web of Science ®Google Scholar
• Floor S, van Staveren WC, Larsimont D, Dumont JE, Maenhaut C. Cancer cells in epithelial-to-mesenchymal transition and tumor-propagating-cancer stem cells: distinct, overlapping or same populations. Oncogene 2011; 30:4609 - 21; http://dx.doi.org/10.1038/onc.2011.184; PMID: 21643013
   PubMed Web of Science ®Google Scholar
• Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO, et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci USA 2011; 108:7950 - 5; http://dx.doi.org/10.1073/pnas.1102454108; PMID: 21498687
   PubMed Web of Science ®Google Scholar
• Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C, et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 2011; 146:633 - 44; http://dx.doi.org/10.1016/j.cell.2011.07.026; PMID: 21854987
   PubMed Web of Science ®Google Scholar
• Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell 2012; 10:717 - 28; http://dx.doi.org/10.1016/j.stem.2012.05.007; PMID: 22704512
   PubMed Web of Science ®Google Scholar
• Jordan NV, Johnson GL, Abell AN. Tracking the intermediate stages of epithelial-mesenchymal transition in epithelial stem cells and cancer. Cell Cycle 2011; 10:2865 - 73; http://dx.doi.org/10.4161/cc.10.17.17188; PMID: 21862874
   PubMed Web of Science ®Google Scholar
• Abollo-Jiménez F, Jiménez R, Cobaleda C. Physiological cellular reprogramming and cancer. Semin Cancer Biol 2010; 20:98 - 106; http://dx.doi.org/10.1016/j.semcancer.2010.02.002; PMID: 20188173
   PubMed Web of Science ®Google Scholar
• Li R, Liang J, Ni S, Zhou T, Qing X, Li H, et al. A mesenchymal-to-epithelial transition initiates and is required for the nuclear reprogramming of mouse fibroblasts. Cell Stem Cell 2010; 7:51 - 63; http://dx.doi.org/10.1016/j.stem.2010.04.014; PMID: 20621050
   PubMed Web of Science ®Google Scholar
• Polo JM, Hochedlinger K. When fibroblasts MET iPSCs. Cell Stem Cell 2010; 7:5 - 6; http://dx.doi.org/10.1016/j.stem.2010.05.018; PMID: 20621040
   PubMed Web of Science ®Google Scholar
• Samavarchi-Tehrani P, Golipour A, David L, Sung HK, Beyer TA, Datti A, et al. Functional genomics reveals a BMP-driven mesenchymal-to-epithelial transition in the initiation of somatic cell reprogramming. Cell Stem Cell 2010; 7:64 - 77; http://dx.doi.org/10.1016/j.stem.2010.04.015; PMID: 20621051
   PubMed Web of Science ®Google Scholar
• Chen T, Yuan D, Wei B, Jiang J, Kang J, Ling K, et al. E-cadherin-mediated cell-cell contact is critical for induced pluripotent stem cell generation. Stem Cells 2010; 28:1315 - 25; http://dx.doi.org/10.1002/stem.456; PMID: 20521328
   PubMed Web of Science ®Google Scholar
• Redmer T, Diecke S, Grigoryan T, Quiroga-Negreira A, Birchmeier W, Besser D. E-cadherin is crucial for embryonic stem cell pluripotency and can replace OCT4 during somatic cell reprogramming. EMBO Rep 2011; 12:720 - 6; http://dx.doi.org/10.1038/embor.2011.88; PMID: 21617704
   PubMed Web of Science ®Google Scholar
• Lowry WE. E-cadherin, a new mixer in the Yamanaka cocktail. EMBO Rep 2011; 12:613 - 4; http://dx.doi.org/10.1038/embor.2011.117; PMID: 21701504
   PubMed Web of Science ®Google Scholar
• Tuma RS. Cancer stem cell hypothesis and trastuzumab in HER2-negative tumors. J Natl Cancer Inst 2012; 104:968 - 9; http://dx.doi.org/10.1093/jnci/djs307; PMID: 22745473
   PubMed Web of Science ®Google Scholar
• Liu YN, Abou-Kheir W, Yin JJ, Fang L, Hynes P, Casey O, et al. Critical and reciprocal regulation of KLF4 and SLUG in transforming growth factor β-initiated prostate cancer epithelial-mesenchymal transition. Mol Cell Biol 2012; 32:941 - 53; http://dx.doi.org/10.1128/MCB.06306-11; PMID: 22203039
   PubMed Web of Science ®Google Scholar
• Lin ZS, Chu HC, Yen YC, Lewis BC, Chen YW. Krüppel-like factor 4, a tumor suppressor in hepatocellular carcinoma cells reverts epithelial mesenchymal transition by suppressing slug expression. PLoS One 2012; 7:e43593; http://dx.doi.org/10.1371/journal.pone.0043593; PMID: 22937066
   PubMedGoogle Scholar
• Yori JL, Johnson E, Zhou G, Jain MK, Keri RA. Kruppel-like factor 4 inhibits epithelial-to-mesenchymal transition through regulation of E-cadherin gene expression. J Biol Chem 2010; 285:16854 - 63; http://dx.doi.org/10.1074/jbc.M110.114546; PMID: 20356845
   PubMed Web of Science ®Google Scholar
• Yori JL, Seachrist DD, Johnson E, Lozada KL, Abdul-Karim FW, Chodosh LA, et al. Krüppel-like factor 4 inhibits tumorigenic progression and metastasis in a mouse model of breast cancer. Neoplasia 2011; 13:601 - 10; PMID: 21750654
   PubMed Web of Science ®Google Scholar
• Yu F, Li J, Chen H, Fu J, Ray S, Huang S, et al. Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion. Oncogene 2011; 30:2161 - 72; http://dx.doi.org/10.1038/onc.2010.591; PMID: 21242971
   PubMed Web of Science ®Google Scholar
• Daley GQ. Common themes of dedifferentiation in somatic cell reprogramming and cancer. Cold Spring Harb Symp Quant Biol 2008; 73:171 - 4; http://dx.doi.org/10.1101/sqb.2008.73.041; PMID: 19150965
   PubMedGoogle Scholar
• Werbowetski-Ogilvie TE, Bhatia M. Pluripotent human stem cell lines: what we can learn about cancer initiation. Trends Mol Med 2008; 14:323 - 32; http://dx.doi.org/10.1016/j.molmed.2008.06.005; PMID: 18635398
   PubMed Web of Science ®Google Scholar
• Blum B, Benvenisty N. The tumorigenicity of human embryonic stem cells. Adv Cancer Res 2008; 100:133 - 58; http://dx.doi.org/10.1016/S0065-230X(08)00005-5; PMID: 18620095
   PubMed Web of Science ®Google Scholar
• Blum B, Benvenisty N. The tumorigenicity of diploid and aneuploid human pluripotent stem cells. Cell Cycle 2009; 8:3822 - 30; http://dx.doi.org/10.4161/cc.8.23.10067; PMID: 19887907
   PubMed Web of Science ®Google Scholar
• Wobus AM. The Janus face of pluripotent stem cells--connection between pluripotency and tumourigenicity. Bioessays 2010; 32:993 - 1002; http://dx.doi.org/10.1002/bies.201000065; PMID: 21105293
   PubMed Web of Science ®Google Scholar
• Castellanos A, Vicente-Dueñas C, Campos-Sánchez E, Cruz JJ, García-Criado FJ, García-Cenador MB, et al. Cancer as a reprogramming-like disease: implications in tumor development and treatment. Semin Cancer Biol 2010; 20:93 - 7; http://dx.doi.org/10.1016/j.semcancer.2010.02.001; PMID: 20188174
   PubMed Web of Science ®Google Scholar
• Ben-David U, Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer 2011; 11:268 - 77; http://dx.doi.org/10.1038/nrc3034; PMID: 21390058
   PubMed Web of Science ®Google Scholar
• Ramos-Mejia V, Fraga MF, Menendez P. iPSCs from cancer cells: challenges and opportunities. Trends Mol Med 2012; 18:245 - 7; http://dx.doi.org/10.1016/j.molmed.2012.04.001; PMID: 22521522
   PubMed Web of Science ®Google Scholar
• Zhang X, Cruz FD, Terry M, Remotti F, Matushansky I. Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency-based reprogramming. Oncogene 2012; In press http://dx.doi.org/10.1038/onc.2012.237; PMID: 22777357
   PubMed Web of Science ®Google Scholar
• Lang JY, Shi Y, Chin YE. Reprogramming cancer cells: back to the future. Oncogene 2012; In press http://dx.doi.org/10.1038/onc.2012.349; PMID: 22869153
   PubMed Web of Science ®Google Scholar
• Dewi D, Ishii H, Haraguchi N, Nishikawa S, Kano Y, Fukusumi T, et al. Reprogramming of gastrointestinal cancer cells. Cancer Sci 2012; 103:393 - 9; http://dx.doi.org/10.1111/j.1349-7006.2011.02184.x; PMID: 22151786
   PubMed Web of Science ®Google Scholar
• Oak PS, Kopp F, Thakur C, Ellwart JW, Rapp UR, Ullrich A, et al. Combinatorial treatment of mammospheres with trastuzumab and salinomycin efficiently targets HER2-positive cancer cells and cancer stem cells. Int J Cancer 2012; 131:2808 - 19; http://dx.doi.org/10.1002/ijc.27595; PMID: 22511343
   PubMed Web of Science ®Google Scholar
• Zhu Y, Zhang X, Liu Y, Zhang S, Liu J, Ma Y, et al. Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo. Tumour Biol 2012; 33:1349 - 62; http://dx.doi.org/10.1007/s13277-012-0383-6; PMID: 22492237
   PubMed Web of Science ®Google Scholar
• Masuko K, Okazaki S, Satoh M, Tanaka G, Ikeda T, Torii R, et al. Anti-tumor effect against human cancer xenografts by a fully human monoclonal antibody to a variant 8-epitope of CD44R1 expressed on cancer stem cells. PLoS One 2012; 7:e29728; http://dx.doi.org/10.1371/journal.pone.0029728; PMID: 22272243
   PubMed Web of Science ®Google Scholar
• Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, Martin-Castillo B, Joven J, Menendez JA. Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis. Cell Cycle 2010; 9:4461 - 8; http://dx.doi.org/10.4161/cc.9.22.14048; PMID: 21088486
   PubMed Web of Science ®Google Scholar
• Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Del Barco S, Martin-Castillo B, Lopez-Bonet E, et al. The anti-diabetic drug metformin suppresses the metastasis-associated protein CD24 in MDA-MB-468 triple-negative breast cancer cells. Oncol Rep 2011; 25:135 - 40; PMID: 21109968
   PubMed Web of Science ®Google Scholar
• Cirenajwis H, Smiljanic S, Honeth G, Hegardt C, Marton LJ, Oredsson SM. Reduction of the putative CD44+CD24- breast cancer stem cell population by targeting the polyamine metabolic pathway with PG11047. Anticancer Drugs 2010; 21:897 - 906; http://dx.doi.org/10.1097/CAD.0b013e32833f2f77; PMID: 20838207
   PubMed Web of Science ®Google Scholar
• Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle 2010; 9:1057 - 64; http://dx.doi.org/10.4161/cc.9.6.10994; PMID: 20305377
   PubMed Web of Science ®Google Scholar
• Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Del Barco S, Martin-Castillo B, Menendez JA. Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. Cell Cycle 2010; 9:3807 - 14; http://dx.doi.org/10.4161/cc.9.18.13131; PMID: 20890129
   PubMed Web of Science ®Google Scholar
• Del Barco S, Vazquez-Martin A, Cufí S, Oliveras-Ferraros C, Bosch-Barrera J, Joven J, et al. Metformin: multi-faceted protection against cancer. Oncotarget 2011; 2:896 - 917; PMID: 22203527
   PubMed Web of Science ®Google Scholar
• Vazquez-Martin A, López-Bonetc E, Cufí S, Oliveras-Ferraros C, Del Barco S, Martin-Castillo B, et al. Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions. Drug Resist Updat 2011; 14:212 - 23; PMID: 21600837
   PubMed Web of Science ®Google Scholar
• Oliveras-Ferraros C, Cufí S, Vazquez-Martin A, Torres-Garcia VZ, Del Barco S, Martin-Castillo B, et al. Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: induction of the tumor suppressor miRNA let-7a and suppression of the TGFβ-induced oncomiR miRNA-181a. Cell Cycle 2011; 10:1144 - 51; http://dx.doi.org/10.4161/cc.10.7.15210; PMID: 21368581
   PubMed Web of Science ®Google Scholar
• Liu JC, Voisin V, Bader GD, Deng T, Pusztai L, Symmans WF, et al. Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERα- breast cancer. Proc Natl Acad Sci USA 2012; 109:5832 - 7; http://dx.doi.org/10.1073/pnas.1201105109; PMID: 22460789
   PubMed Web of Science ®Google Scholar
• Giordano A, Gao H, Anfossi S, Cohen E, Mego M, Lee BN, et al. Epithelial-Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer. Mol Cancer Ther 2012; 11:2526 - 34; http://dx.doi.org/10.1158/1535-7163.MCT-12-0460; PMID: 22973057
   PubMed Web of Science ®Google Scholar
• Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J, et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci USA 2010; 107:15449 - 54; http://dx.doi.org/10.1073/pnas.1004900107; PMID: 20713713
   PubMed Web of Science ®Google Scholar
• Kim H, Watkinson J, Varadan V, Anastassiou D. Multi-cancer computational analysis reveals invasion-associated variant of desmoplastic reaction involving INHBA, THBS2 and COL11A1. BMC Med Genomics 2010; 3:51; http://dx.doi.org/10.1186/1755-8794-3-51; PMID: 21047417
   PubMed Web of Science ®Google Scholar
• Anastassiou D, Rumjantseva V, Cheng W, Huang J, Canoll PD, Yamashiro DJ, et al. Human cancer cells express Slug-based epithelial-mesenchymal transition gene expression signature obtained in vivo. BMC Cancer 2011; 11:529; http://dx.doi.org/10.1186/1471-2407-11-529; PMID: 22208948
   PubMed Web of Science ®Google Scholar
• Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application?. J Clin Oncol 2005; 23:7350 - 60; http://dx.doi.org/10.1200/JCO.2005.03.3845; PMID: 16145060
   PubMed Web of Science ®Google Scholar
• Generali D, Berruti A, Foroni C, Bazzola L, Andreis D, Allevi G, et al. Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design. J Natl Cancer Inst Monogr 2011; 2011:67 - 70; http://dx.doi.org/10.1093/jncimonographs/lgr029; PMID: 22043044
   PubMedGoogle Scholar
• Inoue A, Seidel MG, Wu W, Kamizono S, Ferrando AA, Bronson RT, et al. Slug, a highly conserved zinc finger transcriptional repressor, protects hematopoietic progenitor cells from radiation-induced apoptosis in vivo. Cancer Cell 2002; 2:279 - 88; http://dx.doi.org/10.1016/S1535-6108(02)00155-1; PMID: 12398892
   PubMed Web of Science ®Google Scholar
• Kajita M, McClinic KN, Wade PA. Aberrant expression of the transcription factors snail and slug alters the response to genotoxic stress. Mol Cell Biol 2004; 24:7559 - 66; http://dx.doi.org/10.1128/MCB.24.17.7559-7566.2004; PMID: 15314165
   PubMed Web of Science ®Google Scholar
• Wu WS, Heinrichs S, Xu D, Garrison SP, Zambetti GP, Adams JM, et al. Slug antagonizes p53-mediated apoptosis of hematopoietic progenitors by repressing puma. Cell 2005; 123:641 - 53; http://dx.doi.org/10.1016/j.cell.2005.09.029; PMID: 16286009
   PubMed Web of Science ®Google Scholar
• Leroy P, Mostov KE. Slug is required for cell survival during partial epithelial-mesenchymal transition of HGF-induced tubulogenesis. Mol Biol Cell 2007; 18:1943 - 52; http://dx.doi.org/10.1091/mbc.E06-09-0823; PMID: 17344479
   PubMed Web of Science ®Google Scholar
• Valdés F, Alvarez AM, Locascio A, Vega S, Herrera B, Fernández M, et al. The epithelial mesenchymal transition confers resistance to the apoptotic effects of transforming growth factor Beta in fetal rat hepatocytes. Mol Cancer Res 2002; 1:68 - 78; PMID: 12496370
   PubMed Web of Science ®Google Scholar
• Vega S, Morales AV, Ocaña OH, Valdés F, Fabregat I, Nieto MA. Snail blocks the cell cycle and confers resistance to cell death. Genes Dev 2004; 18:1131 - 43; http://dx.doi.org/10.1101/gad.294104; PMID: 15155580
   PubMed Web of Science ®Google Scholar
• Barrallo-Gimeno A, Nieto MA. The Snail genes as inducers of cell movement and survival: implications in development and cancer. Development 2005; 132:3151 - 61; http://dx.doi.org/10.1242/dev.01907; PMID: 15983400
   PubMed Web of Science ®Google Scholar
• Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, et al. CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 2006; 8:R59; http://dx.doi.org/10.1186/bcr1610; PMID: 17062128
   PubMed Web of Science ®Google Scholar
• Honeth G, Bendahl PO, Ringnér M, Saal LH, Gruvberger-Saal SK, Lövgren K, et al. The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res 2008; 10:R53; http://dx.doi.org/10.1186/bcr2108; PMID: 18559090
   PubMed Web of Science ®Google Scholar
• Ricardo S, Vieira AF, Gerhard R, Leitão D, Pinto R, Cameselle-Teijeiro JF, et al. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J Clin Pathol 2011; 64:937 - 46; http://dx.doi.org/10.1136/jcp.2011.090456; PMID: 21680574
   PubMed Web of Science ®Google Scholar
• Laakso M, Loman N, Borg A, Isola J. Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod Pathol 2005; 18:1321 - 8; http://dx.doi.org/10.1038/modpathol.3800456; PMID: 15990899
   PubMed Web of Science ®Google Scholar
• van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 2002; 161:1991 - 6; http://dx.doi.org/10.1016/S0002-9440(10)64476-8; PMID: 12466114
   PubMed Web of Science ®Google Scholar
• Liu H, Fan Q, Zhang Z, Li X, Yu H, Meng F. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers. Hum Pathol 2008; 39:167 - 74; http://dx.doi.org/10.1016/j.humpath.2007.06.012; PMID: 18045647
   PubMed Web of Science ®Google Scholar
• Bagaria SP, Ray PS, Wang J, Kropcho L, Chung A, Sim MS, et al. Prognostic value of basal phenotype in HER2-overexpressing breast cancer. Ann Surg Oncol 2012; 19:935 - 40; http://dx.doi.org/10.1245/s10434-011-2032-5; PMID: 21879270
   PubMed Web of Science ®Google Scholar
• Tripathi MK, Misra S, Chaudhuri G. Negative regulation of the expressions of cytokeratins 8 and 19 by SLUG repressor protein in human breast cells. Biochem Biophys Res Commun 2005; 329:508 - 15; http://dx.doi.org/10.1016/j.bbrc.2005.02.006; PMID: 15737616
   PubMed Web of Science ®Google Scholar
• Li XY, Zhou X, Rowe RG, Hu Y, Schlaepfer DD, Ilić D, et al. Snail1 controls epithelial-mesenchymal lineage commitment in focal adhesion kinase-null embryonic cells. J Cell Biol 2011; 195:729 - 38; http://dx.doi.org/10.1083/jcb.201105103; PMID: 22105351
   PubMed Web of Science ®Google Scholar